Biocon settles Genentech’s US patent dispute over Perjeta biosimilar

A global settlement resolves patent disputes over Biocon’s proposed breast cancer biosimilar, Pebrilzo, and sets a licensed US launch window for the third quarter of 2028, subject to regulatory approval.

Biocon Biologics has reached a global patent settlement and licensing agreement with Genentech, resolving a US patent dispute over its proposed biosimilar of the breast cancer treatment Perjeta and establishing a timetable for market entry.

Biocon announced the agreement on October 14, 2026, confirming that it resolves pending patent disputes between the companies in the United States, Canada, and other jurisdictions. The financial and other terms of the agreement remain confidential.

Under the agreement, Biocon has secured licensed launch dates for Pebrilzo, its biosimilar to Perjeta (pertuzumab). The company plans to launch the product in the United Kingdom and European Union in the first quarter of 2027, followed by the United States in the third quarter of 2028, subject to regulatory approval.

US patent litigation

Genentech, a subsidiary of Swiss pharmaceutical group Roche, filed a patent infringement lawsuit against Biocon Biologics in the US District Court for the District of New Jersey in July 2026. The case, Genentech Inc. v. Biocon Biologics Inc., No. 2:26-cv-09585, concerned Biocon’s proposed biosimilar of Perjeta.

Genentech alleged that Biocon’s efforts to obtain regulatory approval for the product infringed 28 patents associated with Perjeta. The lawsuit sought to prevent the proposed biosimilar from entering the US market.

According to Bloomberg Law, Genentech and its parent company, Hoffmann-La Roche, subsequently notified the court that they were voluntarily dismissing their infringement claims without prejudice.

The dismissal followed the companies’ settlement. Although Biocon’s announcement states that the agreement resolves the pending disputes between the parties, the confidential terms have not been disclosed, limiting the extent to which the precise scope of the licensing arrangements can be assessed independently.

The settlement does not constitute a judicial finding that Genentech’s patents are invalid or that Biocon’s proposed product would not infringe them.

Licensed launch dates established

Perjeta is a biologic medicine containing pertuzumab, a monoclonal antibody used to treat HER2-positive breast cancer. Biocon’s Pebrilzo is being developed as a biosimilar alternative.

Under the global settlement and license agreement, Biocon has announced the following planned launch timetable:

• United Kingdom and European Union: First quarter of 2027.
• United States: Third quarter of 2028.
• Other markets: During 2026–2028, with earlier launches possible in certain circumstances.

The company has emphasized that launches in all markets remain subject to regulatory approval.

The agreement provides greater visibility over the timing of potential competition with Perjeta, particularly in the US market, where the patent dispute had created uncertainty over the proposed biosimilar’s entry.

However, the settlement does not itself authorize the sale of Pebrilzo. Regulatory approval and compliance with the applicable requirements will remain necessary before the product can be marketed in each jurisdiction.

Implications for pharmaceutical patent strategy

The dispute illustrates the role of patent settlements and licensing agreements in determining the timing of biosimilar competition.

For biosimilar developers, negotiated agreements can provide greater certainty over launch dates while reducing the expense and risks associated with prolonged litigation. For originator companies, licensing arrangements can establish the conditions under which competing products may enter the market. For Biocon, the settlement establishes a defined pathway toward launching Pebrilzo in several major markets. The extent of the commercial opportunity will depend on regulatory decisions, market conditions and the eventual timing of entry.

The agreement also highlights the importance of patent strategy in the biologics sector, where multiple patents may cover different aspects of a reference medicine, including its composition, formulation, manufacturing processes, and methods of treatment. While the settlement removes a significant litigation obstacle for Biocon, the confidential terms mean that the full scope of the parties’ agreed rights and obligations remains undisclosed.

← Back to News